caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines

Archives

Current

November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011

 

Tuesday, January 13, 2009
Fingolimod is better than Avonex!
 
And not just because it's a once a day pill! Less relapses too! Yay! I was particularly happy to see that Novartis will be seeking FDA approval at the end of this year!

"Fingolimod, an oral drug under development for treating multiple sclerosis, was shown to be more effective than current treatments in a recent trial.

The trial consisted of over 1,200 individuals receiving either fingolimod or Avonex. On average, the people receiving Avonex had 0.33 relapses per year while the people on fingolimod had between 0.16 and 0.20 relapses (depending on dosage tested).

The full results have not been released yet, but the company that owns the drug, Novartis, will submit for FDA approval by the end of 2009. That means there could be an effective oral MS treatment available in 2010. This is great news to all of us who deal with side effects and injection site reactions on a daily/weekly/monthly basis."